Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial
Authors:
- Robert S SandlerRSRobert S Sandler
- Robert S BresalierRBRobert S Bresalier
- Angel LanasALAngel Lanas
- Dion G MortonDMDion G Morton
- Robert RiddellRRRobert Riddell
- Erik R IversonEIErik R Iverson
- David L DeMetsDDDavid L DeMets
- 1 November 2008
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 372 (9651) , 1756-1764
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- COX-2 Inhibitors, Other NSAIDs, and Cardiovascular RiskJAMA, 2006
- Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal AdenomasCirculation, 2006
- Adverse Cardiovascular Effects of RofecoxibNew England Journal of Medicine, 2006
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- Cyclooxygenases: new forms, new inhibitors, and lessons from the clinicThe FASEB Journal, 2004
- Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgeryThe Journal of Thoracic and Cardiovascular Surgery, 2003
- Epidemiology of Non-Steroidal Anti-Inflammatory Drugs and Cancer2003
- Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2Nature Reviews Cancer, 2001
- Cyclooxygenase in biology and diseaseThe FASEB Journal, 1998